Compound preparation of active ingredients of traditional Chinese medicine for treating non-alcoholic fatty liver disease and its use

A technology for fatty liver disease and active ingredients, which is applied to medical preparations containing active ingredients, organic active ingredients, pharmaceutical formulations, etc., and can solve the problems of lack of microscopic analysis of medicinal substances and quality control of components.

Active Publication Date: 2019-01-15
LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The traditional Chinese medicine compound focuses on the overall comprehensive treatment, and its mechanism of action is multi-target effect, but it lacks the microscopic analysis of the effective substances and the quality control of the components, which has become the bottleneck of the rapid development of Chinese medicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound preparation of active ingredients of traditional Chinese medicine for treating non-alcoholic fatty liver disease and its use
  • Compound preparation of active ingredients of traditional Chinese medicine for treating non-alcoholic fatty liver disease and its use
  • Compound preparation of active ingredients of traditional Chinese medicine for treating non-alcoholic fatty liver disease and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Embodiment 1 (screening out effective medicinal composition and optimal medicinal composition ratio scheme)

[0032] First determine the safe dose of the medicinal components, and then intervene the fatty degeneration cells with the monomer for 24 hours. (ALT) and aspartate aminotransferase (AST) activity levels to evaluate the drug efficacy, and then carry out dose compatibility of the effective monomers and screen the optimal ratio scheme according to the above indicators.

[0033] 1. Establishment of Steatosis Cell Model

[0034] Stimulate HepG2 and L02 cells with 1 mM free fatty acid (FFA), containing different ratios of oleic acid and palmitic acid, for 24 hours, and observed a large number of lipid droplets in the cells by oil red staining with an inverted optical microscope. ALT activity in the cell supernatant was induced by fatty acids. After 24h, it was significantly up-regulated compared with the control, indicating that the simple steatosis model and the ...

Embodiment 2

[0045] Example 2 ( Describe the pharmacodynamic mechanism of the optimal drug ingredient ratio scheme)

[0046] Select the most effective drug for lowering lipid and transaminase and the compatibility F to intervene in HepG2 cells with steatosis, and conduct a preliminary study on the mechanism of further pharmacodynamics, mainly including oxidative stress and lipid metabolism-related signaling molecules.

[0047] 1. Mechanisms related to oxidative stress

[0048] Firstly, the effect of the drug on the content of oxygen free radicals in the cells is detected. The fluorescent probe DCFH-DA was used to detect intracellular reactive oxygen species (ROS). The control cells had no obvious green fluorescence, but the cells in the model group had strong green fluorescence, indicating that the steatotic liver cells established with 1mmol / L oleic acid and palmitic acid In the presence of oxidative stress, drug F can significantly reduce the ROS content ( Figure 4 ). Malondialdehy...

Embodiment 3

[0051] Embodiment 3 ( Optimum ratio of ingredients to test drug efficacy in mice)

[0052] SPF grade male C57BL / 6 mice, about 20g, were randomly divided into control group (C), model group (M), high dose of F (HF), medium dose of F (MF), low dose of F (LF) and berberine group (BBR). Except for the control group which was given normal feed, the rest were given 60% high-fat feed. After 3 weeks of modeling, each intervention group was intragastrically administered the corresponding drugs for 4 weeks. Among them, H, middle and low groups were given drug F 52, 26, 13 mg / kg / day respectively, and BBR group was given berberine 100 mg / kg / day. After 4 weeks of drug intervention, the patients were fasted for 8 hours, weighed, the eyeballs were removed, blood was collected, and the serum was separated and frozen for testing. The cervical vertebrae were dislocated and sacrificed, and the liver tissue was weighed. Fix in 10% formaldehyde. Serum and liver indicators were detected.

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a compound preparation with effective components of traditional Chinese medicine for treating non-alcoholic fatty liver diseases. The compound preparation is characterized in that the compound preparation comprises three effective components, namely, protopanoxadiol, tanshinone IIA and emodin, of the traditional Chinese medicine, and a molar ratio of protopanoxadiol to tanshinone IIA to emodin is (10-100) to (10-100) to (1-10). The compound preparation with the effective components of the traditional Chinese medicine can be prepared into clinically commonly used preparations such as tablets, granules, capsules or oral liquid according to conventional methods. The compound preparation with the effective components of the traditional Chinese medicine has the advantages that various medicines in different doses and proportions are compatible with one another by the aid of the weight formula methods and are screened by means of intervening liver cell fatty degeneration effects induced by fatty acid, accordingly, the liver cell fatty degeneration can be obviously improved, the lipid level of mice with non-alcoholic fatty livers can be lowered, and liver fat accumulation and liver cell injury of the mice can be relieved.

Description

technical field [0001] The invention belongs to the field of research, development and utilization of traditional Chinese medicine, and in particular relates to a compound preparation of active ingredients of traditional Chinese medicine for treating nonalcoholic fatty liver disease and its application. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) summarizes a class of diseases ranging from simple fatty liver, nonalcoholic steatohepatitis (NASH) to liver fibrosis and even cirrhosis. With the prevalence of obesity and diabetes, the incidence of NAFLD has risen rapidly, becoming one of the most important pathogenic factors of chronic liver disease. In Western populations, the incidence of NAFLD is 25-30%, and it is as high as 80% in obese and diabetic patients, becoming the primary cause of abnormal liver enzymes. In my country, due to changes in dietary structure and lifestyle, the incidence of NAFLD has gradually increased, and it has become the se...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/58A61P1/16A61K31/122A61K31/575
Inventor 宋海燕季光刘洋王立娟张莉徐汉辰
Owner LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap